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Abstract
Human melanoma is a significant clinical problem. As most melanoma patients relapse with lethal drug-resistant
disease, understanding and preventing mechanism(s) of resistance is one of the highest priorities to improve mela-
noma therapy. Melanosomal sequestration and the cellular exportation of cytotoxic drugs have been proposed to
be important melanoma-specific mechanisms that contribute to multidrug resistance in melanoma. Concretely, we
found that treatment of melanoma with methotrexate (MTX) altered melanogenesis and accelerated the exporta-
tion of melanosomes; however, the cellular and molecular processes by which MTX is trapped into melanosomes
and exported out of cells have not been elucidated. In this study, we identified myosin Va (MyoVa) as a possible
mediator of these cellular processes. The results demonstrated that melanoma treatment with MTX leads to Akt2-
dependent MyoVa phosphorylation, which enhances its ability to interact with melanosomes and accelerates their
exportation. To understand the mechanism(s) by which MTX activates Akt2, we examined the effects of this drug
on the activity of protein phosphatase 2A, an Akt inhibitor activated by the methylation of its catalytic subunit.
Taken together, this study identified a novel trafficking pathway in melanoma that promotes tumor resistance
through Akt2/MyoVa activation. Because of these findings, we explored several MTX combination therapies to
increase the susceptibility of melanoma to this drug. By avoiding MTX exportation, we observed that the E2F1
apoptotic pathway is functional in melanoma, and its induction activates p73 and apoptosis protease-activating
factor 1 following a p53-autonomous proapoptotic signaling event.
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Introduction
During the past 30 years, the incidence and annual mortality of
melanoma has increased more rapidly than any other cancer, and
according to an American Cancer Society estimate, there were approx-
imately 76,250 new invasive melanoma cases diagnosed in 2012 in
the United States, which resulted in approximately 9180 deaths
[1]. Unfortunately, this increase in incidence has not been paral-
leled by the development of new therapeutic agents with a signifi-
cant impact on survival and metastatic melanoma is still an incurable
disease. Although many patients with melanoma localized to the
skin are cured by surgical excision, other patients with advanced dis-
ease who have lymph node involvement or distant metastases have
5-year survival rates of 50% and 10% to 20%, respectively [2];
this poor prognosis largely results from melanoma resistance to
conventional chemotherapy [3–8]. In this context, the identifica-
tion of novel pathways in melanoma, susceptible of drug targeting,
might help to develop novel therapies and drug combinations to
improve treatment efficacy and avoid drug resistance in this malig-
nant pathology.
Accumulating evidence has indicated that melanosomes contribute
to the refractory properties of melanoma cells by sequestering cyto-
toxic drugs and increasing melanosome-mediated drug export [4–7].
On the basis of these observations, it has been suggested that prevent-
ing melanosomal sequestration of cytotoxic drugs, by inhibiting the
functions of melanosomes, may have great potential as an approach
to improving the chemosensitivity of melanomas [4]. Recently, several
mutational and RNA interfering approaches have identified novel
protein-trafficking molecules involved in melanoma resistance; mela-
noma cells depleted of genes such as gp100/Pmel17, Dtnbp1, Pldn,
Vps33a, or Hps6, which participate in biogenesis or trafficking of
melanosomes, showed increased sensitivity to cisplatin and other cyto-
toxic drugs [6,7]. However, despite the great advances in the knowledge
of this multidrug resistance mechanism, the processes by which drugs
are trapped into melanosomes and exported out of cells remains largely
undetermined and the existence of drug-based therapies, to suppress
this mechanism of resistance, is still limited.
To identify novel druggable targets into this multidrug resistance
mechanism, we evaluated the resistance of melanoma to metho-
trexate (MTX), a drug in widespread clinical use but is not actively
used for melanoma treatment [9]. As for other drugs, we have recently
observed that the folate receptor α–mediated endocytotic transport of
MTX facilitates melanosomal drug sequestration and cellular expor-
tation in melanoma cells, thereby reducing the accumulation of MTX
in intracellular compartments [5]. Therefore, to achieve our objective,
we focused our attention on the MTX effects on myosin Va (MyoVa),
an actin-based motor protein involved in vesicle trafficking during
exocytosis [10]. We observed that the MyoVa protein was specifi-
cally phosphorylated in response to MTX treatment, stimulating
MyoVa-dependent melanosome transport. Therefore, once we elu-
cidated the molecular mechanisms leading to MTX-dependent
MyoVa activation in melanoma, we tested whether pharmacologic
blockade of the MyoVa pathway could overcome MTX resistance
in these cells. Because melanoma cells are intrinsically resistant to
classic antifolates [11], the death pathways triggered in melanomas
in response to this class of drugs have never been studied. Therefore,
in addition to its clinical potential, this study allowed us to analyze,
for the first time, the melanoma susceptibility to classic antifolates
and identify functional apoptosis pathways in this evasive and deadly
cutaneous pathology.
Materials and Methods
Reagents and Antibodies
MTX, 7-hydroxystaurosporine (UCN-01), cantharidin, and Akt
inhibitor (IAKT) VIII trifluoroacetate salt hydrate were obtained
from Sigma-Aldrich (Madrid, Spain). Antibodies against the follow-
ing proteins were used: Akt1, Akt2, phospho-Akt1/2/3-Thr308,
phospho-Akt1/2/3-Ser473, phospho-H2A.X-Ser139, E2F1, p73, pro-
tein phosphatase 2A C (PP2A C) subunit, methyl–PP2A C subunit
(Millipore, Madrid, Spain), Akt3, Akt1/2/3, Melan-A/MART1, p53,
Slac2-a (Santa Cruz Biotechnology, Santa Cruz, CA), MyoVa (Cell
Signaling Technology, Danvers, MA), apoptosis protease-activating
factor 1 (Apaf1; BD Biosciences, Sparks, MD), Pmel17/HMB45
(Dako Inc, Carpinteria, CA), Rab27a (Abcam, Cambridge, United
Kingdom), and β-actin (Sigma).
Cell Lines, Proliferation, and Apoptosis Assays
Melanoma cell lines of human and mouse origin were obtained from
ATCC (Manassas, VA) and maintained in the appropriate culture me-
dium supplemented with 10% FBS and antibiotics. Cell viability was
evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide. Cells were evaluated for apoptosis using the Cell Death
Detection ELISAPLUS Kit (Roche Diagnostics, Barcelona, Spain) that
detects mononucleosomes and oligonucleosomes in the cytoplasmic
fractions of cell lysates using biotinylated anti-histone and peroxidase-
coupled anti-DNA antibodies. The amount of nucleosomes is spectro-
photometrically quantified at 405 nm by the peroxidase activity
retained in the immunocomplexes. Apoptosis was defined as the spe-
cific enrichment of mononucleosomes and oligonucleosomes in the
cytoplasm and was calculated by dividing the absorbance of treated
samples by the absorbance of untreated samples after correcting for
the number of cells. The induction of apoptosis in each melanoma cell
line after a 7-hour treatment with 2 μM staurosporine (100% apoptotic
cells) was used to calculate the number of apoptotic cells.
Polymerase Chain Reaction Analysis
mRNA extraction, cDNA synthesis, and conventional and quan-
titative real-time polymerase chain reaction (PCR) were performed as
previously described [12]. Primers were designed using Primer Express
version 2.0 software (Applied Biosystems, Foster City, CA) and syn-
thesized by Life Technologies (Barcelona, Spain). To quantify the gene
expression level of the MyoVa exon F transcripts, the following primers
were designed for exons E and F [Accession Nos AF090424 and
X57377 for human (h) and mouse (m) transcripts, respectively]:
MyoVa (h) (forward: 5′-GGC TGA CCA ACG AAA ACT TG-3′
and reverse: 5′-TCA TCC GTT TGT AAA GGG AAA T-3′) and
MyoVa (m) (forward: 5′-GGC TGA CCA ATG AAA ACC TG-3′
and reverse: 5′-TCC TTT TGT AAA GTG AAA TCC GAT A-3′).
p73 primers were designed to amplify TAp73 (p73 with the trans-
activating domain; NM_005427.3) transcripts of human origin:
TAp73 (h) (forward: 5′-TGG AAC CAG ACA GCA CCT ACT
TCG-3′ and reverse: 5′-CAG GTG GCT GAC TTG GCC GTG
CTG-3′). Other primers included are given as follows: Apaf1 (h)
(forward: 5′-GCTCTCCAAATTGAAAGGTGAAC-3′ and reverse:
5′-ACT GAA ACC CAA TGC ACT CC-3′) and β-actin (h, m)
(forward: 5′-AGA AAA TCT GGC ACC ACA CC-3′ and reverse:
5′-GGG GTG TTG AAG GTC TCA AA-3′).
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Chromatin Immunoprecipitation Assays
A chromatin immunoprecipitation (ChIP) assay was performed
using the Magna ChIP G Kit from Millipore according to the manu-
facturer’s instructions. Briefly, untreated and MTX- and/or UCN-01–
treated SK-MEL-28 cells were formaldehyde cross-linked, and the
DNA was sheared by sonication to generate an average size of 300 to
3000 bp. The chromatin was then incubated with anti-E2F1 or mouse
IgG antibodies. DNA from lysates before immunoprecipitation was
used as a positive input control. After washing, elution, and DNA
purification, the DNA solution (2 μl) was used as a template for quan-
titative real-time PCR amplification using specific human primers. The
following primer sequences were used for ChIP-PCR: TAp73 promoter
region (forward: 5′-TGAGCCATGAAGATGTGCGAG-3′ and reverse:
5′-GCT GCT TAT GGT CTG ATG CTT ATG-3′) and glyceraldehyde
3-phosphate dehydrogenase (GAPDH ) (forward: 5′-CAA TTC CCC
ATC TCA GTC GT-3′ and reverse: 5′-TAG TAG CCG GGC CCT
ACT TT-3′). Standard curves were generated for all primer sets to
confirm linearity of signals over the experimentally measured ranges.
Interference RNA
Specific stealth siRNAs for MyoVa (HSS106896), p53
(HSS129934 and HSS129936), Akt1 (HSS100345 and HSS100346),
Akt2 (HSS163235 and HSS163236), and Akt3 (HSS115177 and
HSS115179) were obtained from Life Technologies and transfected
into melanoma cells using Lipofectamine 2000 (Life Technologies).
Treatments began 24 hours after siRNA transfection. Stealth RNA
negative control duplexes (Life Technologies) were used as control oligo-
nucleotides, and the ability of the stealth RNA oligonucleotides to
knock down the expression of the selected genes was analyzed by
Western blot analysis 24 hours after siRNA transfection.
Immunoblot Analysis and Immunoprecipitation
Whole-cell lysates were collected by adding sodium dodecyl sulfate
sample buffer. After extensive sonication, the samples were boiled for
10 minutes and subjected to sodium dodecyl sulfate–polyacrylamide
gel electrophoresis. Proteins were then transferred to nitrocellulose
membranes and analyzed by immunoblot analysis (ECL Plus; GE
Healthcare, Barcelona, Spain). For Akt2 immunoprecipitation assays,
the cells (approximately 5 × 106) were lysed in 500 μl of lysis buffer
[50 mM Tris (pH 8.0), 300 mM NaCl, 0.4% NP-40, and 10 mM
MgCl2] supplemented with protease and phosphatase inhibitor cock-
tails (Sigma). Cell extracts were cleared by centrifugation (20,000g
for 15 minutes) and then diluted with 500 μl of dilution buffer
[50 mM Tris (pH 8.0), 0.4% NP-40, and 2.5 mM CaCl2] sup-
plemented with protease and phosphatase inhibitor cocktails and
DNase I (Sigma). Extracts were precleared by a 30-minute incubation
with 20 μl of PureProteome Protein G Magnetic Beads (Millipore) at
4°C with rotation. An Akt2 antibody was then added to the precleared
extracts. After incubation for 1 hour at 4°C, 50 μl of PureProteome
Protein G Magnetic Beads was added, and the extracts were further
incubated for 20 minutes at 4°C with rotation. After extensive washing,
the bound proteins were analyzed by Western blot analysis. Unbound
extracts were used as positive inputs for protein load determination.
Microscopy and Fluorescence Lifetime Imaging Microscopy
EM was performed as previously described [13] using a Zeiss
EM10 electronmicroscope (Carl ZeissMicroImaging, Inc, Thornwood,
NY). Laser scanning confocal microscopy of fixed cells was performed
using a Leica TCS 4D confocal microscope (Wetzlar, Germany). For
indirect immunofluorescence studies, preparations of cells on glass slides
were fixed with cold acetone for 5 minutes and washed with phosphate-
buffered saline (PBS). The cells were incubated with 3% BSA for
20 minutes and then with primary antibodies (diluted 1:200 in PBS
containing 1% BSA) for 2 hours at room temperature. The cells were
washed three times in PBS and incubated for 1 hour at room temper-
ature with Alexa Fluor dyes (Life Technologies) as secondary antibodies.
After three washes with PBS, the cells were incubated with 0.01% 4′-6-
diamidino-2-phenylidene (DAPI; Sigma) in water for 5 minutes. For
antibody specificity, primary antibodies were replaced with specific IgGs
(diluted 1:200) during immunofluorescence. Co-localization analysis
was performed with the Co-localization Finder plugin of ImageJ-NIH
and showed images of the Alexa Fluor 633 (red) merged with Alexa
Fluor 488 (green) secondary antibodies and the co-localized pixels in
orange. This plugin provides the Pearson overlap coefficient (Rr) ranging
from −1 to 1, where 1 represents perfect co-localization, 0 represents
random co-localization, and −1 represents perfect exclusion (http://
rsb.info.nih.gov/ij/plugins/colocalization-finder.html).
The confocal imaging of MTX–fluorescein isothiocyanate (FITC)
in live cells [fluorescence lifetime imaging microscopy (FLIM)] was
performed using the same confocal microscope. Images were col-
lected following 488-nm laser excitation with an FITC emission filter.
Before live confocal microscopy, the cells were incubated in serum-
free Dulbecco’s modified Eagle’s medium (DMEM) for 1 hour with
MTX-FITC and with or without UCN-01. After this time, the cells
were extensively washed with DMEM containing MTX (without
FITC) and with or without UCN-01 as appropriate. During imaging,
the cells were incubated on a heated stage at 37°C in DMEM con-
taining MTX (without FITC) and with or without UCN-01 as ap-
propriate. Frames were collected at the indicated times. Images were
processed with Huygens Essential v. 4.1.0p6 (Scientific Volume
Imaging BV, Hilversum, The Netherlands) and Imaris (Bitplane AG,
Zurich, Switzerland). Vesicle movements were traced, and velocities
and distances were calculated using the ImageJ 1.6.0_20 (National
Institutes of Health, Bethesda, MD) manual tracking plugin (Fabrice
Cordelieres, Institut Curie, Orsay, France). The fluorescence intensity
levels within selected cell areas were also computed using ImageJ, and
the FITC fluorescence intensity was expressed as integrated density
(reactive area multiplied by the mean gray of the same area).
Preparation of Melanoma Cell Granular Fractions
and Sucrose Density Gradients
Control untreated melanoma cells and those subjected to treat-
ments with MTX and/or IAKT were harvested with a mixture of
0.25% trypsin and 0.25 mM EDTA, washed once in 0.25 M sucrose,
and centrifuged at 1000g for 10 minutes at 4°C. Specimens were then
homogenized on ice using 20 strokes in a Potter homogenizer and
centrifuged at 1000g for 10 minutes at 4°C. The supernatant was
recovered and further centrifuged at 19,000g for 30 minutes at 4°C
[14]. The pellet containing melanosome-enriched granular fractions was
resuspended in ice-cold 0.25 M sucrose in 10 mM Hepes (pH 7.0)
and examined by EM. Purified melanoma granular fractions were
resuspended in 2.0 M sucrose and layered at the bottom of a 1.0 to
2.0 M sucrose step (1.0, 1.2, 1.4, 1.5, 1.6, 1.8, and 2.0 M) gradient.
The gradient was centrifuged at 100,000g in a Beckman SW41 swinging
bucket rotor for 1 hour at 4°C.
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PP2A Assay
Cells were exposed to the experimental conditions indicated in the
results. After two washes with 0.9% NaCl, total cellular proteins
were extracted in lysis buffer containing 50 mM Tris·HCl (pH 7.5),
250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 1% Triton X-100,
and 0.5% NP-40 without phosphatase inhibitors. Specific PP2A activ-
ity was measured using the PP2A Immunoprecipitation Phosphatase
Assay Kit (Millipore). All procedures were performed according to
the manufacturer’s protocol, and changes in absorbance were measured
at 650 nm in a Spectra-MAX 250 (Molecular Devices, Sunnyvale, CA)
plate reader.
MTX Conjugation with HRP
MTX (10 mM) was dissolved completely in a pH 7.0 buffer so-
lution (100 mM, phosphate buffer), and then an equimolar quantity
of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride
(EDC; 10 mM) was added. The mixture was stirred for 40 minutes at
room temperature. The activated MTX (1 ml) was added to 10 μM
horseradish peroxidase isozyme C (HRPC) solutions (1 ml, pH 7.0)
and incubated for 18 hours at room temperature. The MTX-conjugated
proteins were separated from unreacted MTX using a Sephadex G-25
desalting column equilibrated in PBS (pH 7.4). The degree of MTX
conjugation was spectrophotometrically determined by measuring the
difference in absorbance between the conjugated and free proteins at
303 nm. HRP has a molecular mass of 40 kDa, and each HRPmolecule
contains six lysine residues. Titration experiments demonstrated that the
total protein lysines were conjugated to MTX and this factor was used
to determine MTX levels in melanoma cells (Figure 4F). The cellular
uptake of MTX-conjugated HRP was performed by treating SK-MEL-
28 melanoma cells (in 96-well plates) for 5 hours with 1 μM MTX-
HRPC in the absence or presence of 50 nM UCN-01. After extensive
washing with ice-cold PBS, the cells were disrupted by adding 200 μl of
HRP activity medium [150 μM 2,2′-azino-bis(3-ethylbenzothiazoline-
6-sulphonic acid) (ABTS) and 75 μMH2O2 in citrate-phosphate buffer,
pH 4.5]. The oxidation of ABTS in the presence of HRP was fol-
lowed by observing the increase in absorbance at 414 nm (Δε414 nm =
31.1 mM−1 cm−1) in a SpectraMax 340PC384 microplate reader
(Molecular Devices).
dNTP Pool Extraction and Analysis
Asynchronously proliferating SK-MEL-28 cells were seeded in six-
well dishes. The extraction and analysis of the dNTP pools in each
extract were performed as previously described [15]. The reaction
mixtures (50 μl) contained 100 mM Hepes buffer (pH 7.5), 10 mM
MgCl2, 0.1 unit of the Escherichia coliDNA polymerase I Klenow frag-
ment (Sigma, Madrid, Spain), 0.25 μM oligonucleotide template, and
1 μCi [3H]dATP (ARC, St Louis, MO) or [3H]dTTP (Perkin-Elmer,
Waltham, MA). Incubations were performed for 60 minutes at 37°C.
Matrix-Assisted Laser Desorption/Ionization-Time-Of-Flight
(MALDI-TOF) Mass Spectroscopy
SK-MEL-28 whole-cell lysates were immunoprecipitated as de-
scribed above. After immunoprecipitation and elution, bound pro-
teins were digested with trypsin according to standard procedures
[16]. The data were recorded and processed with Agilent MassHunter
Workstation Software to obtain the peptide mass fingerprint. The
resulting peptide mass fingerprint mass spectra were searched against
the MyoVa protein sequence with carbamidomethylation of cysteine
as a fixed modification, and variable phosphorylation modifications at
Ser1650 and Ser1812 were searched. The peptide mass tolerance was set
to 50 ppm, and a maximum of three missed cleavages was considered.
Mouse Melanoma Models
Animals were bred and maintained according to the Spanish leg-
islation on the “Protection of Animals Used for Experimental and
Other Scientific Purposes” and in accordance with the directives of
the European community. For the subcutaneous melanoma model,
B16/F10 cells (5.0 × 105) were subcutaneously injected into the
dorsal flanks of 6- to 8-week-old female C57BL/6 mice. Animals
with tumors greater than 8 mm in diameter on day 8 or with no
visible tumor growth by day 12 were excluded. Groups (n = 10 mice
per group) were subjected to treatments beginning on the eighth
day after tumor cell injection. Mice were intradermally treated
with MTX (1 mg/kg per day) and/or UCN-01 (0.1 mg/kg per day)
five times a week for 3 weeks.
Hepatic metastases were produced by the intrasplenic injection of
3.0 × 105 B16-F10-luc2 mouse melanoma cells (Caliper Life
Sciences, Hopkinton, MA) as previously described [17] (n = 10–15).
Primary spleen tumors and hepatic metastases at days 12 and 14,
respectively, were analyzed using the IVIS Imaging System (Caliper Life
Sciences). Mice were intraperitoneally treated with MTX (1 mg/kg per
day) and UCN-01 (0.5 mg/kg per day) from days 1 to 14, and control
mice received the same volume of vehicle (DMSO). Postmortem
histologic liver and spleen examination was performed in all animals.
Formalin-fixed paraffin-embedded tissue sections were stained with
hematoxylin and eosin. A Leica DMRB microscope connected to
a Leica DC500 digital camera was used to quantify the number,
average diameter, and position coordinates of the metastases [17].
For tyrosinase detection, mouse livers (three per treatment) were
cut into approximately 0.2-g slices. Five randomly chosen slices
from each liver were used for phenol-chloroform total RNA extrac-
tion. The RNA (5 μg) was then used to synthesize cDNA, and equal
amounts of the five cDNA fractions corresponding with the same
liver were pooled and employed for tyrosinase mRNA determina-
tions using quantitative real-time PCR (tyrosinase primers—for-
ward: 5′-GGG CCC AAA TTG TAC AGA GA-3′ and reverse:
5′-ATG GGT GTT GAC CCA TTG TT-3′).
Statistical Analysis
For experiments, the mean ± SD for five determinations in tripli-
cate were calculated. Numeric data were analyzed for statistical sig-
nificance using the Mann-Whitney U test for comparisons of mean
values with the Statistical Package for the Social Sciences statistical
software for Microsoft Windows, version 6.0 (Professional Statistic,
Chicago, IL). Individual comparisons were analyzed with an un-
paired two-tailed Student’s t test. The criterion for significance was
P < .05 for all comparisons.
Results
MTX Stimulates MyoVa-Dependent Melanosome Transport
The treatment of melanoma with MTX has been reported to
accelerate melanosome exportation [5]. Here, we used FLIM to follow
MTX-FITC–containing vesicles trafficking in SK-MEL-28 melanoma
cells. Figure 1A demonstrates selected images from a typical experiment.
Upon MTX-FITC addition, fluorescent vesicles migrated from the cy-
tosol to the plasma membrane, and before being exported out of the
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cells, they transiently accumulated in the dendritic tips of melanoma
cells. It has been reported that melanosomes can be transported to
melanocyte dendrites by the microtubule-based motor protein KIF3,
and the subsequent movement of these vesicles and their tethering at
the cell membrane is dependent onMyoVa and F-actin [18,19]. Because
MTX-FITC treatment transiently increased fluorescent-containing
vesicles in the actin-rich periphery of the dendrites, the effect of MTX
on the endogenous MyoVa localization in SK-MEL-28 was further an-
alyzed by immunocytochemistry. Thus, an anti-MyoVa antibody was
used in combination with the melanosomal marker HMB45 to analyze
the distribution of melanosomes and their possible association with
MyoVa inmelanoma cells. As observed in Figure 1B, melanosomes were
found perinuclear but did not co-localize with MyoVa in untreated cells
(as determined by Pearson overlap coefficients); in contrast, after the
Figure 1. MTX activates MyoVa-dependent melanosome transport in melanoma. (A) Selected stills obtained by FLIM of MTX-FITC–
containing vesicles in SK-MEL-28 cells treated with 20 μM MTX-FITC (1 hour). After extensive washing, the cells were imaged at one
frame per minute for 1 hour in the presence of 20 μM unlabeled MTX. Time courses for the fluorescence intensity (arbitrary units) inside
the boxed region of interest are shown. Fluorescent MTX-FITC–containing exosomes were visible during the recording time. (B) Immuno-
histochemistry (IHC)wasperformed to analyze the localizationofMyoVa in untreatedSK-MEL-28cells and in cells treated for 10hourswith1μM
MTX. Upper panels show localization ofMyoVa (red) and themelanosome stage II marker, HMB45 (green); DAPI is represented in blue. Lower
panels represent merged images of the localization of MyoVa (red) and DAPI (blue) with Slac2-a or Rab27a (both in green). From the confocal
images, a Pearson coefficient was calculated to estimate the degree of co-localization of the different melanosome markers with MyoVa
(histograms). The Pearson overlap coefficients are represented as the average of 10 individual cells. *P< .05 with respect to untreated control
cells. (C) MyoVa silencingmodifiesMTX-FITC distribution in SK-MEL-28melanoma cells. Cells were imaged after 1-hour treatment with 10 μM
MTX-FITC. (D) MyoVa siRNA sensitizes SK-MEL-28 toMTX-induced toxicity. Upper panel: Apoptosis was determined after 72-hour treatments
(*P < .05 with respect to siControl (siCN)–treated cells; see Materials and Methods section). Lower panel: The effective silencing of MyoVa
was tested by Western blot (WB) and relative to β-actin expression.
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treatment of cells with MTX, MyoVa was localized in the cell periphery
and the tips of the dendrites and associated with melanosomes. Co-
localization studies of MyoVa with Rab27a and melanophilin/Slac2-a,
two MyoVa-assistant proteins that contribute to melanosome transport
[20,21], also suggested that MTX activated MyoVa-dependent mela-
nosome transport in the amelanotic SK-MEL-28 melanoma cell line
(Figure 1B). Activation of MyoVa-dependent melanosome transport
by MTX was also confirmed in B16/F10, a highly melanotic murine
cell line (Figure W1).
MyoVa Silencing Sensitizes Melanoma Cells to
MTX-Induced Apoptosis
In melanocytes, MyoVa is required for the capture of melano-
somes in actin-rich cell protrusions, and its specific silencing resulted
in the dispersion of melanosomes in the cytoplasm [22]. Therefore,
we next examined whether transient MyoVa silencing could sensitize
melanoma cells to MTX by impeding its melanosome-mediated
exportation (Figure 1C ). SK-MEL-28 cells were transfected with
siRNA-MyoVa or a control siRNA and maintained in culture medium
in the presence or absence of MTX. The results presented in Figure 1D
demonstrate that efficient MyoVa knockdown significantly increased
the sensitivity of SK-MEL-28 cells to MTX-induced apoptosis.
MTX Leads to MyoVa Phosphorylation in Melanoma
Because MyoVa appeared to be an attractive target for avoiding
MTX resistance in melanoma, we next sought to define the signaling
pathways stimulated by MTX that result in the activation of MyoVa
in these cells. First, we analyzed changes in the MyoVa expression
levels after the treatment of melanoma cells with MTX. Real-time
PCR and Western blot experiments indicated that MTX did not sig-
nificantly increase the MyoVa mRNA and protein levels in these cells
(Figure W2, A and B). Recent studies have provided evidence that
the MyoVa protein is a direct Akt2 substrate in adipocytes. In addi-
tion, Akt2-dependent MyoVa phosphorylation enhances its ability to
interact with the actin cytoskeleton and GLUT4 vesicles [23]. There-
fore, we next analyzed whether MTX treatment promoted MyoVa
Figure 2.MTX activates the Akt-dependent phosphorylation of MyoVa in melanoma. (A) Effects of 1 μMMTX on Akt phosphorylation in
melanoma cells. (B) IHC to analyze the location of Akt1/2/3 and PP2A in SK-MEL-28 (1 μMMTX). (C) Effect of IAKT (10 hours) on the MTX-
induced phosphorylation of MyoVa (*P < .05). (D) Left panel: Density gradients of enriched melanosomal fractions obtained from
untreated SK-MEL-28 cells and cells treated (5 hours) with 10 μMMTX and/or 10 μM IAKT. Right panel: EM experiments. (E) Histograms
represent the effects of MTX/IAKT treatment (2 days) on SK-MEL-28 (*P < .05 with respect to IAKT-treated cells). Increasing IAKT con-
centrations were analyzed in the absence or presence of 1 μMMTX. The images show the effects of MTX and/or IAKT treatments on cell
morphology. (F) siCN- and siAkt-transfected cells were treated with 1 μMMTX (48 hours; *P < .05). Akt silencing was examined by WB.
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phosphorylation in melanoma. MyoVa has two Akt consensus motifs
at Ser1650 (RKRTSS) and Ser1812 (RDRKDS), which are highly con-
served across mammalian species. By using mass peptide analysis of
immunoprecipitated MyoVa after trypsin digestion, we observed that
MTX specifically promoted its phosphorylation at Ser1650 (FigureW2C
and Table W1).
MTX Activates Akt2-Dependent Phosphorylation of
MyoVa in Melanoma
Western blot experiments indicated that MTX stimulates Akt phos-
phorylation at Thr308 and Ser473 in melanoma cell (Figure 2A). Akt
activation by MTX was also confirmed with confocal microscopy
experiments (Figure 2B), and it was found that activated Akt proteins
translocated into the nucleus, coinciding with phosphorylation. MTX
activation of the Akt-dependent phosphorylation of MyoVa in mela-
noma was also demonstrated by co-treatment of melanoma cells with
MTX and a specific IAKT. The presence of IAKT during MTX treat-
ments was sufficient to inhibit MyoVa phosphorylation and melano-
some export (Figure 2, C and D), which resulted in a substantial
increase in the sensitivity of melanoma cells to MTX-induced apoptosis
(Figure 2E). Although the results indicated that MTX stimulated Akt
phosphorylation, the identification of which Akt isoforms were acti-
vated by this drug in these experiments is difficult. Therefore, to iden-
tify which form of Akt may be involved in MyoVa activation in
melanoma, we used siRNAs directed against the three Akt isoforms.
For these experiments, SK-MEL-28 cells were transfected with these
different siRNAs, and after 48 hours, the sensitivity of the transfected
cells to MTX-induced apoptosis was determined. Each siRNA led to a
marked depletion of the target protein (Figure 2F), but only the Akt2
knockdown significantly increased the sensitivity of the melanoma cells
to MTX-induced apoptosis. In contrast, Akt1 and Akt3 knockdown
had only marginal effects on MTX-induced apoptosis.
MTX Induces Demethylation of the Catalytic PP2A C
Subunit and Inhibits PP2A Activity
In addition to nucleotide imbalance, a decrease in cellular methyla-
tion has been overlooked as a mechanism for the antiproliferative
effects of MTX in cancer cells [24]. Because PP2A is now believed
to dephosphorylate Akt at the Thr308 phosphoinositide-dependent
kinase-1 (PDK1) phosphorylation site, an attractive hypothesis that
may link the MTX demethylating properties with Akt activation in
melanoma is that MTX may inactivate PP2A, an IAKT activated
by methylation of its catalytic subunit, before being exported from
cells [25]. To test this hypothesis, we performed Western blot analy-
sis, which demonstrated that MTX induced the demethylation of the
PP2A on its catalytic subunit (Figure 3A). In agreement with this
observation, MTX-dependent PP2A demethylation was also accom-
panied by a substantial time- and dose-dependent reduction in PP2A
activity (Figure 3B) and a lack of its co-localization with Akt in the
cytosolic compartment (Figure 2B). Next, we used cantharidin, a potent
and selective inhibitor of PP2A, to confirm the consequences of PP2A
inhibition on MyoVa activation in melanoma cells (Figure 3C ).
UCN-01 Inhibits the MTX-Induced Activation of MyoVa and
Prevents MTX Exportation in Melanoma Cells
Full Akt activation appears to require the phosphorylation of
Thr308 and Ser473 by PDK1 and the putative PDK2, respectively.
Because UCN-01 has been shown to potently inhibit PDK1 [26],
Figure 3. MTX induces demethylation of the catalytic PP2A C subunit and inhibits PP2A activity in melanoma cells. (A) Time-dependent
effects of MTX (1 μM) on the methylation status of the catalytic PP2A C subunit (Leu309) in SK-MEL-28. (B) The histograms represent the
time (at 1 μMMTX) and dose (at 60 minutes) effects of MTX on PP2A activity. *P < .05 compared with untreated controls. (C) Treatment
of SK-MEL-28 melanoma cells during 24 hours with MTX or cantharidin (both at 1 μM) promoted the co-localization of MyoVa (red) with
the melanosome stage II marker, HMB45 (green). DAPI is represented in blue. Merged images are shown. From the confocal images, a
Pearson coefficient was calculated to estimate the degree of co-localization of MyoVa with HMB45 (histograms). The Pearson overlap
coefficients are represented as the average of 10 individual cells. *P < .05 with respect to untreated control cells.
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we hypothesized that the inhibition of Akt2 phosphorylation by
UCN-01 may result in the disruption of MTX-stimulated melanosome
transport. To validate this hypothesis, we examined the Akt2 phos-
phorylation state in total melanoma cell homogenates (Figure 4A).
When cells were treated with UCN-01 in the presence of MTX, we
observed a significant decrease in Akt2 phosphorylation (with re-
spect to MTX-treated cells) at the Thr308 and Ser473 residues, which
is consistent with PDK1 being the UCN-01 molecular target [26].
MALDI-TOF mass spectra of MyoVa tryptic peptides demonstrated
that UCN-01–mediated Akt phosphorylation inhibition also resulted
Figure 4. UCN-01 prevents MTX exportation in melanoma cells. (A) WB demonstrating the effects of UCN-01 on MTX-induced Akt2
phosphorylation. SK-MEL-28 cells were treated (1 hour) with 1 μM MTX or 1 μM MTX plus 50 nM UCN-01. (B) The effect of UCN-01
on the MTX-induced phosphorylation of MyoVa and its cellular localization. IHC was performed in SK-MEL-28 treated (10 hours) with
1 μM MTX or 1 μM MTX plus 50 nM UCN-01. (C) Subsecond frame-rate confocal microscopy examining the movements of individual
MTX-FITC–containing vesicles. SK-MEL-28 cells were treated with 20 μM MTX-FITC or 20 μM MTX-FITC plus 50 nM UCN-01 for 1 hour.
After extensive washing, the cells were imaged at two frames per second for 60 seconds in the presence of unlabeled MTX or MTX/
UCN-01. Images at time zero are represented in green and those at 60 seconds are represented in red. (D) FLIM of MTX-FITC–containing
vesicles in SK-MEL-28 treated with 20 μM MTX-FITC and 50 nM UCN-01 (1 hour). After extensive washing, the cells were imaged at
one frame per minute for 1 hour in the presence of 20 μM unlabeled MTX and 50 nM UCN-01. Time courses of the fluorescence
intensity inside the boxed regions of interest are shown. (E) Intracellular accumulation of MTX-FITC in SK-MEL-28 treated (4 hours) with
MTX-FITC (20 μM) and MTX-FITC/UCN-01 (20 μM/50 nM). (F) HRP activity in SK-MEL-28 after treatment (4 hours) with MTX-HRP (1 μM)
with and without UCN-01 (50 nM).
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in a significant reduction in the MTX-induced MyoVa phosphoryla-
tion at Ser1650 (Figure 4B). Consequently, with this lack of MyoVa
activation, we observed that UCN-01 prevented the MTX-mediated
translocation of MyoVa to the melanoma dendritic tips (Figure 4B).
Given the remarkably dynamic nature of the MTX-FITC vesicle
subpopulation observed in Figure 1A, we next used subsecond
frame-rate confocal microscopy to examine the movement of indi-
vidual MTX-FITC–containing vesicles in basal SK-MEL-28 cells
(Figure 4C ). Fluorescent vesicles were observed to make directed move-
ments over short distances at speeds ranging from 0.077 to 0.004 μm/s
(average, 0.035 μm/s). However, in the presence of UCN-01, MTX-
FITC vesicles remained fairly static over this time course, showing
vibrational-type displacements but not moving far from their original
location (Figure 4C). Because of this vesicle immobility, fluorescence
was mainly associated with cytoplasmic compartments, and it did not
migrate to the dendritic tips at longer time periods (Figure 4,D and E).
Figure 5. MTX/UCN-01 treatment induces E2F1-mediated apoptosis in melanoma. MTX (1 μM) and/or UCN-01 (50 nM) was used.
(A) Synergy test for melanoma cell lines. MTX and UCN-01 were combined in 6 × 6 matrices where the concentration of one drug was
increased along each axis. Apoptosis (4 days post-treatment) was obtained in triplicate in two-independent experiments. Differences in
apoptosis in MTX/UCN-01–treated cells were significant with respect to individual treatments for each drug concentration (P < .05).
MTX/UCN-01 combination showed clear synergistic behavior [45]. (B) dNTP quantification in melanoma cells. The data (left panel) were
used to determine the total amount of each dNTP at each time point. The right panel represents dTTP levels in melanoma cells sub-
jected to the indicated treatments (24 hours). *P < .05 with respect to untreated controls; **P = .001; ***not statistically significant
with respect to the untreated controls. (C) SK-MEL-28 cells subjected to the indicated treatments (24 hours) were examined for γH2AX
foci and DAPI. (D) WB of several melanocytic proteins after MTX/UCN-01 treatment (24 hours). Protein levels are relative to β-actin and
the expression of these proteins in untreated controls (one-fold). (E) Left panel: Quantitative real-time PCR of TAp73 and Apaf1 mRNA.
SK-MEL-28 cells were treated with the indicated treatments (24 hours). mRNA levels are presented relative to β-actin mRNA and com-
pared with their expression levels in untreated cells (one-fold). Right panel: E2F1 occupancy on the TAp73 promoter of SK-MEL-28
subjected to the indicated treatments (24 hours).
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Finally, in an attempt to quantify theMTX accumulation in melanoma
cells, we conjugated MTX to HRP, which served as a reporter enzyme
(Figure 4F).
Suppression of MTX Exportation in Melanoma Cells Promotes
E2F1-Mediated Apoptosis
Although UCN-01 exhibited potent antitumor activity in several
in vivo and in vitro tumor models, this drug is inactive in melanomas
[27]. However, when this drug was combined with MTX, we observed
that apoptosis was strongly induced in melanoma cell lines indepen-
dently of the mutational status of the p53, BRAF, and PTEN genes
(Figure 5A). Although p53 is usually wild type in melanoma, apoptosis
triggered by MTX/UCN-01 treatment was independent of p53 muta-
tion status and was not affected by p53 silencing in G361 cells
(Figure W3). It is well known that antifolates induce dTTP depletion
in sensitive cancer cells, and more recently, it has been proposed that
“thymineless” death may be mediated by the E2F1 apoptotic cascade
[28]. However, MTX fails to increase E2F1 protein levels in melanoma
cells [9]. Because we previously hypothesized that this resistance mech-
anism was favored by low intracellular MTX levels in melanoma cells
[5,9], we analyzed whether the higher MTX accumulation in the pres-
ence of UCN-01 could modify dTTP and E2F1 cellular levels. As ob-
served in Figure 5, B and C , the treatment of melanoma cells with
MTX/UCN-01 generated a nucleotide imbalance that favored dTTP
depletion and the subsequent increase of E2F1 protein. Thymidine
depletion induces DNA double-strand break (DSB) formation charac-
terized by phosphorylation of histone H2AX at Ser139 (γH2AX) by
ATM/ATR kinases and the subsequent rapid formation of γH2AX foci
at the double-strand break sites [29]. Consistent with the effects of
combination treatment being mediated through thymidine depletion,
immunofluorescence revealed that combined MTX/UCN-01 treat-
ment of SK-MEL-28 cells induced massive DNA damage in melanoma
cells (Figure 5, C andD). In addition, Western blot and real-time PCR
analyses (Figure 5, C and E ) indicated that when combined with
UCN-01, MTX induced the expression of both the transactivating form
of p73 (TAp73) and Apaf1, two proapoptotic targets of E2F1 [30]. ChIP
assays also indicated that, compared with untreated cells or those sub-
jected to individual treatments, the MTX/UCN-01 combination sig-
nificantly increased the occupancy of E2F1 at the TAp73 promoter of
SK-MEL-28 (Figure 5E). Because Chk1 and Chk2 are vital to E2F1 sta-
bilization and activity after genotoxic stress, we next checked whether
these checkpoint kinases were phosphorylated after MTX/UCN-01
treatment (Figure 5C ). Altogether, these results indicated that the
accumulation of MTX in cells co-treated with UCN-01 activated an
E2F1-mediated but p53-independent cell death signaling in melanoma.
UCN-01 Enhances In Vivo Melanoma Sensitivity to MTX
The profound effects of this combination in vitro led us to test its
antitumorigenic efficacy in vivo. In an initial approach, B16/F10 cells
were subcutaneously injected into C57BL/6 mice, a syngeneic mela-
noma model in which host mice retain intact immune systems. Visual
examination revealed that the MTX/UCN-01 combination acted
synergistically to inhibit tumor growth (Figure 6A). Using B16 cells
that express a luciferase reporter (Figure 6A), quantification of the
in vivo luciferase signal confirmed that the MTX/UCN-01 combi-
nation was highly effective at reducing the primary tumor burden.
A histologic study of primary splenic tumors suggested that MTX/
UCN-01 treatment induced necrosis in B16/F10 tumors. As vehicle
controls, B16/F10 tumors treated with DMSO showed their usual
histologic appearance of poor differentiation and limited necrosis
(Figure 6A). In contrast, 14-day treatment withMTX/UCN-01 induced
obvious hemorrhagic necrosis, with necrotic areas of approximately
85%. Necrosis in splenic tumors was less evident in mice treated with
MTX or UCN-01 (4 ± 2% and 2 ± 0.5%, respectively).
As an alternative approach, we tested whether MTX/UCN-01
administration after the injection of melanoma cells could prevent
melanoma dissemination from the spleen to the liver, one of the pref-
erential metastatic locations for melanomas. Luciferase-tagged B16/
F10 cells were injected into the spleens of C57BL/6 mice, and after
14 days of treatment, the number of macroscopic liver metastases was
assessed using a dissecting microscope (Figure 6B). Luciferase imag-
ing demonstrated that mice treated with MTX/UCN-01 had an
appreciably lower burden of macroscopic liver metastases compared
with the untreated control (Figure 6B). To confirm the bioluminescent
results, the livers were analyzed by histology at necropsy (Figure 6C).
MTX/UCN-01 treatment reduced the hepatic metastasis volume by
50% compared with control mice treated with vehicle. Interesting,
MTX/UCN-01 eliminated sinusoidal-type metastasis, and only a lim-
ited number of portal-type metastases were observed after treatment
(Figure 6C ). These data were also confirmed by a real-time PCR anal-
ysis designed to detect melanoma-specific tyrosinase in mouse livers
(Figure 6D).
Discussion
Here, we demonstrated that MyoVa plays a key role in the resistance
of melanoma to MTX, indicating that the targeting of this protein in
the presence of MTX may prevent drug exportation. However, al-
though direct MyoVa inhibition may be a conceptually attractive
strategy for melanoma therapy, its lack of a ligand-binding pocket
or measurable catalytic activity makes it a challenging drug target.
Therefore, we identified the signaling pathways converging during
the MTX-induced activation of MyoVa to design drug-based thera-
pies that will indirectly target this protein in melanoma. In general,
the data provided in this study indicate a close homology between
two vesicular transport processes: the MTX-induced exportation of
melanosomes in melanoma cells and insulin-stimulated GLUT4
membrane translocation in adipocytes. In both processes, the Akt2-
dependent phosphorylation of MyoVa appears to be the trigger for
vesicle cargo trafficking [23,31]. Together with Akt2, protein kinase
Cλ (PKCλ), another phosphoinositol 3-kinase (PI3K)–dependent
serine/threonine kinase, has been found to be necessary for insulin-
induced glucose transport and GLUT4 translocation [32]. It is well
known that insulin simultaneously stimulates the PKCλ/KIF3 and
Akt/MyoVa pathways throughout the activation of the PI3K arm;
however, how MTX simultaneously activates these molecular path-
ways is unknown. Interestingly, it has been recently observed that
PP2A works as a negative regulator of the insulin metabolic signaling
pathway by promoting the dephosphorylation and inactivation of Akt
and PKCλ [33]. Therefore, the observation that MTX inhibited PP2A
activity by inhibiting the methylation of its catalytic subunit appears
to indicate that PP2A inactivation may be a part of its mechanism of
action (Figure 7).
In mammals, the Akt protein signaling kinase has been implicated
in the regulation of widely divergent cellular processes, such as metab-
olism, differentiation, proliferation, and apoptosis. Activation of Akt
is known to protect against apoptosis induced by a number of stimuli
[8,34,35], and several proapoptotic proteins, such as the BH3-only
protein Bad, forkhead transcription factors, and caspase-9, have been
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Figure 6. MTX and UCN-01 combination therapy is effective in vivo. (A) Treatment: 1 and 0.5 mg/kg per day for MTX and UCN-01,
respectively. Left upper panel: B16/F10 cells were subcutaneously injected into C57BL/6 mice. Means are representative of three inde-
pendent experiments. Differences after 21 days of MTX/UCN-01 treatments were statistically significant (P < .002) with respect to con-
trol mice or those subjected to individual MTX and UCN-01 treatments. Left lower panel: Representative luciferase imaging of the
control and MTX/UCN-01–treated mice 12 days after the intrasplenic injection of tumor cells. NS, not significant. Right panel: Effect
of MTX/UCN-01 on B16/F10 primary splenic tumors. Xenograft tumors treated (14 days) with DMSO (vehicle) or MTX/UCN-01. Vehicle-
treated tumors showed normal splenic tissue (S) and tumor areas (T) but no discernible necrosis (N). MTX/UCN-01–treated tumors
showed hemorrhagic (H) necrosis. Scale bar, 40 μm. (B) Bioluminescent liver imaging 14 days after the intrasplenic injection of B16-
F10-luc2 cells from untreated and MTX/UCN-01–treated mice. (C) Photomicrograph (three individuals) of hematoxylin and eosin–stained
liver sections from vehicle and MTX/UCN-01–treated mice (5×). Scale bar, 40 μm. (D) Histograms represent the copies of tyrosinase
mRNA for every 1 × 103 copies of β-actin ± SD. *P = .001 between MTX/UCN-01–treated mice and untreated controls (vehicle). Livers
form non-melanoma cell inoculated mice (NT) were used as a control.
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identified as direct targets that mediate this protective response [8].
Concretely, in melanoma, the Akt3 protein but not Akt1 or Akt2
was increased in melanoma cell lines compared with normal melano-
cytes [36]. Therefore, although the PTEN/Akt3 signaling cascade
has long been recognized as a therapeutic target in melanoma that
contributes to the melanoma resistance to chemotherapy [36], the
identification of MyoVa as a novel Akt2 proapoptotic target in mela-
noma might be of general interest. Akt2-mediated MyoVa activation,
discovered here as a consequence of MTX action, may represent a
general drug resistance mechanism of melanoma cells in response to
Akt-activating chemotherapeutic agents [4,6–8] and/or in melanoma
with preexisting high, endogenously upregulated, Akt2 activity. It is
well known that ER stress leads to Akt activation [37], and recently,
the adaptation of melanoma cells to ER stress has been proposed as a
resistance mechanism of these cells to chemotherapeutic drugs [8]. Inter-
estingly, melanoma cells are highly resistant to ER stress–inducing
drugs such as cisplatin and adriamycin [7,8] but also to drugs that did
not cause ER stress such as docetaxel and vincristine, two microtubule-
targeting drugs [8]. In the latter case, it was also reported that human
melanomas under ER stress were more resistant to apoptosis induced
by these drugs due, at least in part, to the activation of the PI3K/Akt
pathway. Therefore our results, showing the molecular link between
the Akt signaling pathway and the cellular export of chemotherapeutic
drugs, might offer a global explanation for multidrug resistance in
melanoma and might be useful to open new avenues for exploring
therapeutical combinations of Akt2 inhibitors with MTX or other
cytotoxic drugs.
Another attractive possibility to suppress this multidrug resistance
mechanism in melanoma might be the inhibition of the PDK1 path-
way (Figure 7). Interestingly, UCN-01 decreased insulin-stimulated
glucose transport by inhibition of Akt Thr308 phosphorylation in iso-
lated rat adipose cells [38]. However, although we precisely demon-
strated that UCN-01 inhibited the MTX-induced activation of MyoVa
and prevented MTX export in melanoma cells, we cannot exclude that
UCN-01–dependent inhibition of other cellular kinases, such as Chk1,
might also contribute to the high degree of synergy observed between
both drugs in in vitro and in vivo melanoma models [39]. In fact, this
checkpoint kinase has been shown to protect melanomas from MTX-
induced apoptosis [9]. Because of the potential for entering the clinical
arena, MTX/UCN01 combination, irrespective of the precise action
mechanism, must be taken into consideration in the future design of
melanoma therapies. MTX is in widespread clinical use for a variety of
steroid-recalcitrant inflammatory diseases, and UCN-01 has been
included in multiple clinical trial regimes [40,41]; thus, MTX/UCN-
01 therapy has the potential for rapid application in the human setting.
It is well known that the amino acid sequence encoded by an alter-
natively spliced exon, exon F, is necessary for the selective binding of
MyoVa to melanosomes [22,42]. The MyoVa isoforms lacking this
Figure 7. Proposed mechanism for MTX-induced melanosome transport in melanoma. PP2A is a trimeric serine/threonine phosphatase
that contains the regulatory subunit B, which is recruited by a C-A dimer composed of the catalytic subunit C (PP2AC) and structural
subunit A. Recruitment occurs when C is carboxyl-methylated on the terminal Leu309, resulting in the assembly of the active PP2A
trimer. Reversible PP2A methylation is catalyzed by two conserved PP2A-specific enzymes: leucine carboxyl methyltransferase (LCMT-1)
and PP2A methylesterase (PME-1). Because LCMT1 is a specific S-adenosyl-L-methionine (SAM)-dependent methyltransferase, the treat-
ment of melanoma cells with MTX may result in the inhibition of the PP2A assembly. The left branch, corresponding with KIF3 activation,
is hypothetical and inspired by the insulin-stimulated GLUT4 vesicle translocation process. If an atypical PKC does activate KIF3 in mela-
noma, UCN-01 treatment would result in the disruption of MTX-stimulated microtubule and actin-dependent melanosome transport
because PDK1 is positioned upstream of the Akt and PKC pathways [46]. Green arrows represent MTX-activated pathways, whereas red
lines indicate the site of action for the assayed drugs UCN-01 and IAKT.
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amino acid sequence are not targeted to the melanosomes but local-
ized to the perinuclear region instead [22,42]. Although all the mela-
noma cell lines used in this study presented observable levels of
MyoVa exon F expression (Figure W2A), determination of the levels
of this MyoVa spliced variant in melanoma biopsy samples could be
of interest from a clinical point of view. On the basis of the data
obtained in this study, MyoVa could be considered as an oncogenic
protein that promotes melanoma resistance to anticancer drugs;
therefore, determination of MyoVa exon F in clinical samples of
melanoma patients could help in the design of personalized therapies.
Although combined therapies to target the Akt2/MyoVa pathway
would be functional in melanoma cells having an operative melano-
some trafficking system, melanomas showing low or no expression of
MyoVa exon F, or related trafficking protein, would not be a clinical
problem, because these melanomas would be sensible to classic
monotherapy treatments. Therefore, oncologists could decide the
most appropriate treatment of melanoma patients in function of
MyoVa exon F expression levels in biopsy samples.
In addition to the promising clinical and therapeutic perspectives
of these findings, our results may also have implications for under-
standing the mechanism of action of antifolates in melanoma and
identifying the functionality of the proapoptotic pathways in these
cancer cells. Although E2F1 has been identified as a component of
pathways that link the DNA damage response to cancer cell death
[43], this signaling pathway has been barely explored for melanoma
therapy. Here, we report that the E2F1 apoptotic pathway is func-
tional in melanoma and that its induction activates p73 and Apaf1
following a p53-autonomous proapoptotic signaling event. In addi-
tion, melanoma is often driven by mutations that activate mitogen-
activated protein kinase (MAPK) signaling, such as BRAF [27,44];
therefore, the observation that targeting Akt2/MyoVa in the presence
of MTX, a compound that blocks essential cell metabolic pathways,
induces apoptosis in BRAF-mutated cells may be of potential impor-
tance when designing new treatment strategies to improve chemo-
sensitivity, one of the most important obstacles for the management
of patients with malignant melanoma.
In conclusion, in this study, we identify a multidrug resistance
mechanism that could serve as a link between other resistance mecha-
nisms described in melanoma [4–8]. In this work, the following as-
pects have been addressed: first, we identified MyoVa as a novel and
specific target of Akt2 in melanoma; second, we observed that siRNA
or pharmacological blockade of the Akt2/MyoVa pathway in mela-
noma suppressed MTX resistance in these cancer cells; third, we iden-
tified novel druggable targets in this molecular pathway, which could be
of interest from a clinical point of view; and fourth, we analyzed the
functionality of proapoptotic pathways in melanomas in response to
antifolate treatment, by avoiding the cellular export of MTX. Finally,
we also observed that the Akt2/MyoVa pathway, similar to insulin-
stimulated GLUT4membrane translocation in adipocytes, is conserved
in melanomas. Because this pathway has been extensively characterized
in adipocyte cells, the therapy of melanoma can highly benefit from
these previous studies.
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Figure W1. IHC was performed to analyze the localization of MyoVa
in untreated B16/F10melanoma cells and in cells treated for 4 hours
with 1 μM MTX. Confocal images represent merged images of the
localization of MyoVa with Melan-A/MART1 (melanosome marker)
and Slac2-a. From the confocal images, a Pearson coefficient was
calculated to estimate the degree of co-localization of Melan-A/
MART1 and Slac2-a with MyoVa (histograms). The Pearson overlap
coefficients are represented as the average of 10 individual cells.
*P < .05 with respect to untreated control cells.
Figure W2. MTX leads to MyoVa phosphorylation in melanoma. (A) The effect of MTX (1 μM) on MyoVa–exon F mRNA expression was
assayed by conventional PCR (left panel) and quantitative real-time PCR (right panel). The estimated levels of mRNA relative to β-actin
mRNA in MTX-treated cells were calculated and compared with the expression levels in untreated cells (one-fold). The differences
between the treated cells and their respective untreated controls were not significant. (B) The effect of MTX treatment (1 μM) on MyoVa
protein levels in different melanoma cell lines was assayed by WB using an antibody designed to detect all known MyoVa splice vari-
ants. The MyoVa protein levels were normalized to the β-actin protein levels and their respective controls (one-fold). (C) MALDI-TOF
mass spectra of phosphorylated and non-phosphorylated peptides (at Ser1650) in MyoVa–trypsin-digested samples (Table W1). Peptides
were analyzed in untreated SK-MEL-28 (control) or treated (10 hours) with 1 μM MTX.
Table W1. MALDI-TOF Spectroscopy Properties of Immunoprecipitated MyoVa Tryptic Digests.
Modification MyoVa Status Peptide Sequence* Measured (m/z) Theoretical (m/z) Control† (Intensity)‡ MTX† (Intensity)‡
Phosphorylation (S1650) Non-phosphorylated (R)TSSIADEGTYTLDSILR(Q) 1,841.91 1,841.99 101,324 9,512
Phosphorylated (R)TSpSIADEGTYTLDSILR(Q) 1,921.88 1,921.99 7,835 98,451
Phosphorylation (S1812) Non-phosphorylated (R)KDSPQLLMDAK(H) 1,245.65 1,245.46 112,843 10,514
Phosphorylated (R)KDSpPQLLMDAK(H) 1,325.25 1,325.46 2,305 2,525
*The characteristic peptides involving phosphorylation of MyoVa (phosphorylation, P), as well as their measured and theoretical m/z, are shown.
†Peptides were analyzed in untreated SK-MEL-28 cells (control) and those treated with 1 μM MTX for 10 hours.
‡Relative intensities of specific tryptic peptides were normalized with respect to an internal matrix control.
Figure W3. The effect of p53 silencing on MTX/UCN-01–induced
apoptosis in G361 (p53 wild-type) melanoma cells. MTX (1 μM)
and/or UCN-01 (50 nM) was added to the indicated G361 mela-
noma cells, and apoptosis was determined after 3 days. p53
was silenced in G361 cells as indicated and shown in a WB (inset).
